Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™ Post published:January 20, 2023 Post category:Press Release
Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award Post published:October 20, 2022 Post category:Press Release
Bexson Biomedical Announces Renowned Scientist, Engineer and Inventor, Robert S. Langer ScD, Joins Its Scientific Advisory Board Post published:September 20, 2022 Post category:Press Release
Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SEVALENT™ Post published:September 15, 2022 Post category:Press Release
Bexson Biomedical Announces Participation in the Jeffries Innovation in Mental Health Summit Post published:September 9, 2022 Post category:Press Release
Bexson Biomedical to present at the H.C. Wainwright and Beryl Elites Conferences Post published:June 17, 2022 Post category:Press Release
Bexson Biomedical Launches New Project, Applying Subcutaneous Delivery Technology To Multiple Psychedelic Compounds For Therapeutic Use Post published:August 12, 2021 Post category:Press Release
Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation Post published:April 29, 2021 Post category:Press Release